386 related articles for article (PubMed ID: 11474773)
1. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
2. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
3. [Progress of tailor-made treatment of peptic ulcer].
Aoyama N; Shirasaka D; Okumura K
Nihon Rinsho; 2002 Jan; 60(1):174-81. PubMed ID: 11808330
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
8. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
9. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
[TBL] [Abstract][Full Text] [Related]
12. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
13. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
15. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
[TBL] [Abstract][Full Text] [Related]
16. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
17. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Shirai N; Furuta T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
[No Abstract] [Full Text] [Related]
18. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
[TBL] [Abstract][Full Text] [Related]
19. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
